Cantitate/Preț
Produs

Drugs

Autor Rick Ng
en Limba Engleză Hardback – 22 iun 2015
THIRD EDITION
DRUGS From Discovery to Approval
The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products.
Concise and easy to read, Drugs: From Discovery to Approval, Third Edition quickly introduces basic concepts and then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The third edition incorporates the latest developments and updates in the pharmaceutical community, provides more comprehensive coverage of topics, and includes more materials and case studies suited to college and university use. Biotechnology is a dynamic field with changes across R&D, clinical trials, manufacturing, and regulatory processes; the third edition of the text provides timely updates for those in this rapidly growing field.
  • Revised edition will have greater appeal to students with the inclusion of more materials and case studies suited to college and university use
  • Includes the latest developments and updates
  • Increased appeal by provision of more comprehensive topics
Citește tot Restrânge

Preț: 57898 lei

Preț vechi: 75191 lei
-23% Nou

Puncte Express: 868

Preț estimativ în valută:
10245 12014$ 8998£

Carte disponibilă

Livrare economică 23 ianuarie-06 februarie
Livrare express 09-15 ianuarie pentru 4965 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781118907276
ISBN-10: 1118907272
Pagini: 560
Dimensiuni: 179 x 251 x 32 mm
Greutate: 0.97 kg
Ediția:3rd Revised edition
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Pharmaceutical industry and academic researchers, pharmaceutical managers and executives, healthcare clinicians, policy makers, regulators, and lobbyists with an interest in drug development; graduate students in pharmaceutical science